Medtronic's MiniMed 640G insulin pump is now available in Australia, with additional launches pending local approval. The company says the device represents the latest march toward the development of an artificial pancreas.
Brent Saunders, Actavis chief executive and architect of four major pharma deals, doesn't hate drug discovery. He just doesn't want his company to do it.
Celator Pharmaceuticals received fast-track designation for its candidate for the treatment of secondary acute myeloid leukemia in elderly patients. CPX-351 is designed to achieve sustained release of the anticancer drugs cytarabine and daunorubicin in a precise ratio.
The small, Lexington, MA-based biotech Curis is jumping onto the increasingly popular immuno-oncology bandwagon, handing over a chunk of its stock and promising more than $100 million in milestones to Bangalore-based Aurigene if they can successfully take a small molecule approach to the cancer field and advance a new program through preclinical and clinical development and on into the market. And it's getting a second targeted small molecule for cancer that is intended to hit IRAK4.
Tiny polymer tubes coated with zinc may one day be able to treat stomach conditions such as ulcers by acting as "micromotors" carrying drugs to the stomach lining. Animal studies at the University of California, San Diego, demonstrated in vivo that the synthetic motors enhanced the efficiency of drug delivery to the stomach.
Cashing in on the current enthusiasm in venture circles for gene therapy upstarts, ReGenX has snagged a $30 million round that will finance a round of new hires as it sets sail for the clinic with lead programs for rare diseases of the central nervous system.
Over the past 6 months the up-and-coming Zymeworks has leveraged its expertise in bispecific antibodies into expanded development pacts with two marquee Big Pharma partners. Later today, positioning itself for what it sees as a pivotal year, the biotech plans to announce another research deal with the prolific Big Biotech Celgene, which is inking one of its classic collaborations sweetened by an upfront payment, an equity stake and up to $164 million per project for a slate of programs that represent its biggest potential payoff yet.
Johnson & Johnson has opened the doors on its Takeda-partnered biotech incubator in Israel, enrolling its first class of startups and advancing its global plan to accelerate R&D through external innovation.
Amid an industrywide re-embrace of RNA-based therapies, pioneering biotech Alnylam is plotting to raise $450 million in a public offering, keeping its eye out for pipeline-building acquisitions.
France's Carmat reached another milestone in its quest to bring its artificial heart to market, as a patient who received the device in August has recovered enough to return home.